Notícias

CVS beats Q2 earnings and revenue estimates as stronger segment performance lifts results and prompts raised 2026 guidance, sending shares higher.

CVS Health saw its shares dip about 6% even though it handily beat Wall Street’s expectations for the most recent quarter and raised its guidance for 2026 earnings. The issue was the company’s unusually early commentary about 2027.

(Bloomberg) -- CVS Health Corp. shares fell after the company gave preliminary 2027 profit guidance that disappointed investors and warned of challenges in its pharmacy benefit manager next year, overshadowing a better-than-expected second quarter report.Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealSpaceX’s AI Splurge Puts Damper on Debut Earnings After IPOChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersTaco Bell Met With Michigan on Parasi

Although the revenue and EPS for CVS Health (CVS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

The benchmark US stock measures were trending higher in Wednesday's premarket activity amid growing

CVS Health earnings surged past tepid forecasts after reporting its health benefit costs fell as a share of premiums. The pharmacy chain hiked its full-year outlook by a bit less than the Q2 beat. Analysts say that management's prudence in trying to grow its health benefits business let the company avoid the worst fallout from surprisingly strong medical care utilization.

CVS Health (NYSE:CVS) shares climbed around 5% in pre-market trading on Wednesday after the healthcare company reported second-quarter earnings that comfortably exceeded Wall Street expectations and increased its full-year profit forecast. The company posted earnings of $2.

CVS Health (CVS) delivered earnings and revenue surprises of +37.97% and +5.91%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CVS beat Wall Street expectations by a wide margin in the second quarter and raised its full-year profit forecast to as much as $8.10 per share

Investing.com -- CVS Health shares jumped about 5% in premarket trading Wednesday after the company raised its full-year profit guidance following better-than-expected second-quarter results.

Diversified healthcare company CVS Health (NYSE:CVS) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 7.3% year on year to $106.1 billion. Its non-GAAP profit of $2.58 per share was 39.4% above analysts’ consensus estimates.

CVS Health said it will revamp its weight management program through a partnership with Eli Lilly as the company lifted its full-year outlook and reported a nearly threefold increase in its second-quarter profit.

FEATURE Stock futures were rising on Wednesday, putting both the and the on track to notch record highs. SpaceX slumped 11% in premarket trading after the rockets, telecom, and AI company beat analysts’ second-quarter earnings target but reported higher capital expenditure than Wall Street was expecting.

Today Federal Reserve speakers: Fed governor Lisa Cook Economic data: the Energy Information Administration’s weekly petroleum status report, U.S. services PMI, global services PMI, ADP employment survey Earnings (a.

CVS Health reports earnings Wednesday, with analysts expecting another solid quarter and looking for potential guidance upside from its Aetna insurance and Caremark pharmacy-benefit businesses.

Hims and Hers has 2.6 million subscribers, a battered stock price, and a CEO buying shares instead of signaling an exit. That combination puts a very specific list of giants on alert, and only one of them is a clean fit.

Today Earnings (a.m.): Merck, Pfizer, McDonald's, Caterpillar, Spotify, Apollo, TPG, Marathon Petroleum, Archer-Daniels-Midland, DuPont, Kimberly-Clark Earnings (p.m.): SpaceX, Advanced Micro Devices, ...

The company published the arithmetic of its own margin repair, and the first hard proof landed a quarter before the shares started compounding.

CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

CVS heads into Q2 earnings with estimates pointing to revenue and EPS growth as Aetna initiatives and key business segments support results.

As employers drop coverage for GLP-1 drugs like Wegovy and Zepbound, retail giants are competing to lock in customers through direct-to-consumer programs

In another heavy earnings week, we’ll also see reports from McDonald’s, Disney, Uber, Devon Energy, and more.

Recent earnings expectations and fresh store openings have put CVS Health (CVS) in focus for investors. The stock now sits near US$105 after a strong past year, raising questions about what is already reflected in the price. See our latest analysis for CVS Health. Over the past year, CVS Health has seen its share price move sharply higher, supported by a 90 day share price return of 28.18% and a 1 year total shareholder return of 74.81%. Recent store openings, product launches and...

CVS Health stock has returned 74.8% over the past year, yet its broader valuation checks lean expensive, so investors are weighing a strong share price run against signals that the stock may already be pricing in a lot of good news. Over the last 12 months, CVS Health has delivered a 74.8% return, which puts recent holders in a strong position and naturally raises the bar for what future returns need to justify today’s price. Expectations around CVS Health’s ability to grow healthcare and...

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

Millions of Medicare Advantage members will open a letter this fall that could quietly close doors they assume will always stay open. What insurers have already decided for 2027 and what enrollees do next could cost thousands of dollars or make coverage impossible to find.

The lever behind UnitedHealth stock's climb was a Medicare Advantage repricing management had described months before the run began, and the hard part was believing a plan whose author had just been wrong.

According to the average brokerage recommendation (ABR), one should invest in CVS Health (CVS). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Beyond analysts' top-and-bottom-line estimates for CVS Health (CVS), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

The telehealth company is making a bold pivot that's driving growth, but the stock's recent slide has investors wondering if the price of admission is still too high.